Treatment of Dogs with Oral Melanoma by Hypofractionated Radiation Therapy and Platinum‐Based Chemotherapy (1987–1997)

Freeman, Kim P.; Hahn, Kevin A.; Harris, F. Dee; King, Glen K.

doi:10.1111/j.1939-1676.2003.tb01329.x

Cited by 46 publications

(40 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Macroscopic operative wound healing occurred in 7-9 days, allowing removal of suture materials- fig 7. At recheck, performed at 1, 2, 3, 6 and respectively 12 months from the laser reintervention, there were no evidences of tumour recurrence nor metastasis. Comparison of the obtained data with those reported in other studies (Bergman, 2007;Freeman et …”

Section: Resultssupporting

confidence: 63%

“…Treatment of oral melanomas utilizes the surgical excision-resection (Bradley et al, 1984;Culp et al, 2013;Felizzola et al, 2002;Kosovsky et al, 1991;Wallace et al, 1992) and/or radiation therapy ( Proulx et al, 2003;Freeman et al, 2003), chemotherapy with carboplatin (Brockley et al, 2013;Freeman et al, 2003), immunotherapyvaccines with dendritic cells (Grosenbaugh et al, 2011;Ottnod et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Treatment based on surgical excision is usually palliative (Culp et al, 2013;Freeman et al, 2003) with few studies reporting a curative action, canine oral melanoma having a high rate of relapse -3-28% (Culp et Tuohy et al, 2014), data on the prognosis after laser excision are missing.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Dogs With Oral Melanoma Recurrence by Diode Laser Excision

Igna¹,

Bumb²,

Sicoe³

et al. 2016

BUASVMCN-VM

View full text Add to dashboard Cite

Introduction: Treatment of oral melanomas utilizes the surgical excision-resection (Culp et al., 2013) and/or radiation therapy (Proulx et al., 2003), chemotherapy with carboplatin (Brockley et al., 2013), immunotherapy (Ottnod et al., 2013). Treatment based on surgical excision is usually palliative (Freeman et al., 2003). Aims: In the literature even though there are data concerning the prognosis of oral melanomas in dogs after surgery, are missing data after laser excision. Taking into account these findings we wished to present our experience regarding three cases of oral melanoma recurrence and immediate and long term laser surgery results. Materials and Methods: The casuistry consisted of three dogs with recurrent oral malignant melanomas, subjected to surgical reintervention. The initial diagnosis was melanotic melanoma in stage I or II. The animals were brought back at different time intervals from originally excision with electric scalpel. Before reintervention, dogs were subjected to clinical, paraclinical exam and biopsy. Excision of the tumor mass was made with an optical fiber hawing a diameter of 400µm, at a power of 10W and a wavelength of 940 nm with a diode laser. At 1, 2, 3, 6 and 12 months after laser reintervention the dogs were reexamined. Results: Average time in which appeared canine oral melanoma relapse was 58.6 days. After reexamination all cases where reinstatement in stage I. Operators times were held in conditions of comfort with wide access, minimum bleeding, effective hemostasis. After surgery at 24 hours on the intervention place a slight local redness, without swelling and bleeding was observed. Palpation revealed initially also a slight local sensitivity which completely disappeared in 48 hours. There were no grasping and chewing disturbances. Macroscopic healing occurred in 7-9 days. At last recheck performed at 12 months there were no evidences of tumour recurrence or metastasis. Conclusion: Diode laser excision of oral malignant melanoma in dogs can be an alternative palliative procedure to invasive surgical resection procedures. The average of free recurrence and metastasis time after laser surgery has exceeded 360 days in these three cases.

show abstract

Section: Resultssupporting

confidence: 63%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Dogs With Oral Melanoma Recurrence by Diode Laser Excision

Igna¹,

Bumb²,

Sicoe³

et al. 2016

BUASVMCN-VM

View full text Add to dashboard Cite

show abstract

“…28 When combined with platinum-based chemotherapy, hypofractionated radiation therapy yielded a better outcome with a median survival time of 363 days (n ¼ 39). 29 Sixth, the combined treatment did not produce significant damaging collateral effects. Seventh, to be accepted for clinical practice, any new cancer therapy should not only increase the survival lapse but also improve the quality of life.…”

Section: Discussionmentioning

confidence: 87%

Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma

Finocchiaro

Glikin

2007

Gene Ther

View full text Add to dashboard Cite

We evaluated the safety, efficacy and anti-tumor effects of a surgery adjuvant treatment on canine patients with malignant melanoma. This approach combined suicide gene therapy with a subcutaneous vaccine composed by formolized tumor cells and irradiated xenogeneic cells producing human interleukin-2 and granulocyte-macrophage colony-stimulating factor. The post-surgical margin of the cavity was infiltrated with lipid-complexed thymidine kinase suicide gene coadministrated with ganciclovir. Toxicity was minimal or absent in all patients. With respect to surgery-treated controls (SC), this combined treatment (CT) significantly increased the fraction of patients local disease-free from 6 to 58% and distant metastases-free from 43 to 78% (Fisher's Exact test).In addition, CT significantly improved both SC overall 78 (23-540) and metastasis-free survival 112 (0-467) days to more than 1312 days (respective ranges: 43-1312 and 0-1312) (Kaplan-Meier analysis). In those patients subjected to partial surgery or presenting local recurrence, the efficacy of CT was verified by a 49% of objective responses that averaged 85% of tumor mass loss, while 22% displayed tumor progression as 94% of SC did. Therefore, surgery adjuvant CT controlled tumor growth, delaying or preventing post-surgical recurrence and distant metastasis, significantly extending survival and recovering the quality of life.

show abstract

“…Survival times quoted for conventionally treated stage II or III oral CMM (Table 1.) range from 3-to 12 months with metastasis being a significant cause of mortality (Bateman et al, 1994;Freeman et al, 2003;MacEwen et al, 1986;Murphy et al, 2005;Proulx et al, 2003). It is, however, worth noting that not all oral CMMs are clinically aggressive and some early stage canine patients as well as patients with histologically benign lesions can have extended survivals (MacEwen et al, 1986;Smedley et al, 2011).…”

mentioning

confidence: 99%

Cancer immunology and canine malignant melanoma: A comparative review

Atherton

Morris

McDermott

et al. 2016

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

Canine melanoma as a model of human melanomaFor at least two decades, veterinary oncologists have advocated using spontaneously occurring tumours in companion animals as models for human cancer (Knapp and Waters, 1997;MacEwen, 1990). Several recent reviews have readdressed this approach identifying osteosarcoma, mammary tumours, head and neck cancers, bladder carcinomas, non-Hodgkin lymphoma, prostatic carcinoma, lung cancer and pertinently oral canine malignant melanoma (CMM) as good models for human neoplasms (Hansen and Khanna, 2004;Khanna and Hunter, 2005;Paoloni and Khanna, 2008). The major benefits of dogs as tumour models include the ability to study genetically outbred and immunologically intact animals in which cancers develop spontaneously and thus, more likely reflect the process of tumourigenesis compared to experimentally-induced neoplasms. As pets and owners share the same environment, they may be exposed to the same carcinogens, which, in part, drive tumour development. Regarding disease modelling, animal tumours often have similar clinical presentation, tumour biology and histopathological appearance to their human counterparts and usually progress more rapidly, thereby shortening data maturation times. In addition, few "standard of care" therapies exist for dogs meaning that within reason, trial therapeutics can be instigated at any point. Given these benefits, companion animal tumour models more accurately reflect the features of human cancers compared to rodent models with CMM being a desirable example of one such neoplasm. Conversely, the opportunity to translate the potential value of state of the art human therapeutics to the veterinary clinic also exists. Oral canine malignant melanoma (CMM) is a spontaneously occurring aggressive tumour with relatively few medical treatment options, which provides a suitable model for the disease in humans. Historically, multiple immunotherapeutic strategies aimed at provoking both innate and adaptive anti-tumour immune responses have been published with varying levels of activity against CMM. Recently, a plasmid DNA vaccine expressing human tyrosinase has been licensed for the adjunct treatment of oral CMM. This article reviews the immunological similarities between CMM and the human counterpart; mechanisms by which tumours evade the immune system; reasons why melanoma is an attractive target for immunotherapy; the premise of whole cell, dendritic cell (DC), viral and DNA vaccination strategies alongside preliminary clinical results in dogs. Current "gold standard" treatments for advanced human malignant melanoma are evolving quickly with remarkable results being achieved following the introduction of immune checkpoint blockade and adoptively transferred cell therapies. The rapidly expanding field of cancer immunology and immunotherapeutics means that rational targeting of this disease in both species should enhance treatment outcomes in veterinary and human clinics.

show abstract

Treatment of Dogs with Oral Melanoma by Hypofractionated Radiation Therapy and Platinum‐Based Chemotherapy (1987–1997)

Cited by 46 publications

References 19 publications

Treatment of Dogs With Oral Melanoma Recurrence by Diode Laser Excision

Treatment of Dogs With Oral Melanoma Recurrence by Diode Laser Excision

Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma

Cancer immunology and canine malignant melanoma: A comparative review

Contact Info

Product

Resources

About